At a glance
- Originator Ono Pharmaceutical
- Developer Ono Pharmaceutical; Santen Pharmaceutical
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 18 May 2004 Suspended - Preclinical for Glaucoma in Japan (Ophthalmic)
- 03 Dec 2003 No development reported - Preclinical for Glaucoma in Japan (Ophthalmic)
- 21 Jul 2000 New profile